News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Silica is a proven and highly effective anti-caking agent that has been used for decades
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Aims to achieve CDMO sales of US$ 400 million by 2028
We now rank 3rd in pharmaceutical production by volume and 14th by value
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Subscribe To Our Newsletter & Stay Updated
